SMARCA4 and lung carcinoma: We selected 366 LUAD samples from two lung cancer immunotherapy datasets in cBioPortal; 15% (55/366) of the patients had SMARCA4 mutations (Fig. 5A), including 32 patients (9%) with driver mutations (Fig. 5B).